The Interactions between Heterocyclic Compounds and Target Proteins Involved with Cancer
Abstract
Cancer is the second leading cause of mortality globally. The World Health Organization forecasts that by 2030, there will be 22 million new cases of cancer globally. Extensive global research focuses on cancer prevention, diagnosis, and treatment procedures. The metabolic profile of cancer cells is distinct from that of normal cells, attributable to epigenetic and genetic abnormalities. Numerous anti-cancer drugs available commercially feature heterocycles as their main structural element. Furthermore, anticancer drugs approved by the FDA from 2010 to 2015 contain heterocyclic rings in their chemical structure. Their extensive cellular processes and mechanisms, along with their prevalence in nature, account for their inclusion in anti-cancer medications. This study elucidates several heterocyclic compounds exhibiting anticancer effects on various cell lines. These compounds feature rings composed of nitrogen, sulfur, and oxygen. The collection of information on heterocyclic rings may facilitate the discovery of novel compounds with potential anticancer properties in the future.
Keywords
Download Options
Introduction
Most research has concentrated on VEFG as an initiator; however, various cancer targets have been identified, including enzymes that deacetylate histones, tyrosine kinase, the growth factor TGF-α, fibroblast growth factor (FGF), phosphoglycerate geranylgeranyl transferase (PGF), epidermal growth factor (EGF), and phosphodiesterase types I and II. Despite numerous instances of disease progression post-therapy, inhibition of VEGF signaling has not demonstrated significant efficacy. Numerous heterocyclic anticancer agents, originating from both natural and synthetic sources, are currently utilized, and investigations for further compounds are ongoing. Figure 1 illustrates several instances. The therapeutic properties of heterocyclic compounds, which are cyclic structures containing carbon along with one or more nitrogen, oxygen, or sulfur atoms, have been studied for their potential in treating cancer and various other conditions. Druggable candidates are optimized for ADMET (Adsorption, Distribution, Metabolism, Excretion, and Toxicity) through the introduction of heteroatoms, enhancing their solubility, polarity, and hydrogen bonding capacities. Brevilin A, also referred to as 11, is a natural substance derived from Centipeda minimum. It is a heterocyclic sesquiterpene lactone with demonstrated anticancer properties. Research indicates that Brevilin A may inhibit cell growth, induce apoptosis, and reduce cell metastasis by diminishing the activity of tyrosine kinase, signal transducer, and activator of transcription 3 (STAT3). Lee, Chan, and colleagues synthesized analogues of Brevilin A for their investigation. It was found that compounds 13 and 14, synthesized from paraformaldehyde and 11 via an aldol reaction with sodium carbonate, exhibited greater anticancer efficacy than 11. Cancer therapies frequently encounter issues such as drug resistance, systemic toxicity from treatments, and ineffective medications. Identifying novel anticancer agents as potential drug leads is essential due to the challenges in discovering effective therapeutic agents for tumor treatment. These challenges arise from the inherent variability of cancer cells and the intricate nature of signaling networks.
Conclusion
This study focuses on recent advances in synthesizing anticancer derivatives that incorporate heterocyclic rings, emphasizing the development of targeted anticancer therapies. Anticancer medicines' pharmacokinetic and pharmacodynamic qualities are enhanced by the presence of heterocyclic moieties, which are found in the majority of medications. Approximately 30% of FDA-approved anticancer medications contain one or more heterocyclic rings that include oxygen, nitrogen, and sulfur. Heterocyclic moieties play a significant role in the metabolic reactions that are crucial for the survival of all living organisms. Approximately two-thirds of the anticancer medications approved by the FDA in the first half of the decade incorporated them, highlighting their pivotal role in cancer research and treatment efforts.